Calm Water Therapeutics

Check out the story in BioCentury Inc. by Richard Guy, PhD profiling our company, our scientific platform, and our efforts to deliver new antivirals. https://lnkd.in/e7Z_sC2q

Calm Water Therapeutics' (CWT) PEGPlus technology shows great promise in mitigating ADC induced keratopathy, a serious complication for many receiving ADC based treatments for cancer. In the article, PLL-g-PEG Polymer Inhibits Antibody-Drug Conjugate Uptake into Human Corneal Epithelial Cells In Vitro, the researchers demonstrate virtually complete ADC uptake inhibition with clinically relevant concentrations of PEGPlus. And, in May, CWT released the results from a 30 day dry eye disease study that demonstrated PEGPlus' superior impact on dry eye signs and symptoms. CWT is actively developing products to treat both dry eye and ADC keratopathy. https://lnkd.in/ewGDPAne #ADC #DRYEYEDISEASE #ONCOLOGY

Breakthrough at ARVO 2024 Calm Water Therapeutics (CWT) unveiled exciting results from their second clinical trial at the ARVO 2024 conference, demonstrating the clear efficacy of their proprietary polymer formulation in treating the signs and symptoms of dry eye disease. Conducted in partnership with Ora, the CWT-002 trial evaluated multiple dry eye signs and symptoms over a 30-day period, directly comparing CWT's innovative formulation to the current market leader. CWT's treatment exhibited clear superiority, validating the potential of their cutting-edge technology. CWT is advancing our polymer technology to address not only dry eye disease but also Antibody Drug Conjugate keratopathy, a growing problem that currently lacks an effective solution. This breakthrough could bring much-needed relief to those from these debilitating eye conditions. https://lnkd.in/edz67hah #dryeyedisease #occupationalhealth #oncology

CWT took first prize at the American Academy of Ophthalmology supported Eyecelerator competition. Our approach to the prevention of Antibody Drug Conjugate (ADC) Induced Keratopathy has the potential to drastically improve ADC adherence and the lives of patients. Please take a look. https://lnkd.in/e5CiEMrm #adcs #oncology #dryeyedisease